<SEC-DOCUMENT>0001564590-21-040501.txt : 20210804
<SEC-HEADER>0001564590-21-040501.hdr.sgml : 20210804
<ACCEPTANCE-DATETIME>20210804073402
ACCESSION NUMBER:		0001564590-21-040501
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210804
FILED AS OF DATE:		20210804
DATE AS OF CHANGE:		20210804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		211142358

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190847081

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>bntx-6k_20210804.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-6k_20210804.DOCX.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:20pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:20pt;"><br /></font><font style="font-weight:bold;color:#000000;font-size:20pt;">FORM 6-K</font><font style="color:#000000;font-size:20pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNDER THE SECURITIES EXCHANGE ACT OF 1934<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE MONTH OF AUGUST 2021<font style="font-weight:normal;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMMISSION FILE NUMBER 001-39081 </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE<br /><font style="color:#333333;font-size:10pt;font-weight:normal;">(Translation of registrant&#8217;s name into English)</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">An der Goldgrube 12</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D-55131 Mainz</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Germany</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">+49 6131-9084-0<br /><font style="color:#333333;font-size:10pt;font-weight:normal;">(Address of principal executive offices)</font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F:<font style="color:#000000;"> </font>Form 20&#8209;F <font style="font-family:Segoe UI Symbol;">&#9746;</font> Form 40&#8209;F <font style="font-family:Segoe UI Symbol;">&#9744;</font><font style="color:#000000;"> </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1):<font style="color:#000000;"> </font><font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7)<font style="color:#000000;">: </font><font style="font-family:Segoe UI Symbol;">&#9744;</font> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 4, 2021, BioNTech SE (the &#8220;Company&#8221;) and Kite, Gilead Sciences, Inc. Company, today announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&amp;D platform and clinical manufacturing facility&#8217;s assets and leases in Gaithersburg, MD, from Kite. The press release is attached hereto as Exhibit 99.1.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;">SIGNATURE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<font style="color:#000000;"> </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.63%;"></td>
<td style="width:4.63%;"></td>
<td style="width:44.73%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Dr. Sierk Poetting</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt; border-top:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Dr. Sierk Poetting</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp; Chief Operating Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 4, 2021 </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:12pt;">EXHIBIT INDEX </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:10.98%;"></td>
<td style="width:89.02%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit</font></p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description of Exhibit</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr style="height:22.5pt;">
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="bntx-ex991_7.htm"><font style="text-decoration:underline;">BioNTech completes Acquisition of Kite&#8217;s Neoantigen TCR Cell Therapy R&amp;D Platform and Manufacturing Facility in Gaithersburg, Maryland</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bntx-ex991_7.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex991_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.94%;"></td>
<td style="width:49.94%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzrrpd4jxvgw000001.jpg" title="" alt="" style="width:238px;height:26px;"></p></td>
<td valign="middle" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzrrpd4jxvgw000002.jpg" title="" alt="" style="width:200px;height:60px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">BioNTech completes Acquisition of <br />Kite&#8217;s Neoantigen TCR Cell Therapy R&amp;D Platform and Manufacturing Facility in Gaithersburg, Maryland</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">MAINZ, Germany &amp; Santa Monica, USA, 4. August 2021 &#8211; <font style="text-decoration:underline;font-weight:normal;">BioNTech SE</font><font style="font-weight:normal;">&#160;(Nasdaq: BNTX, &#8220;BioNTech&#8221;) and </font><font style="text-decoration:underline;font-weight:normal;">Kite,</font><font style="font-weight:normal;"> a Gilead Company (Nasdaq: GILD, &#8220;Kite&#8221;) today announced the closing of the acquisition of the solid tumor neoantigen T cell receptor (TCR) R&amp;D platform and clinical manufacturing facility&#8217;s assets and leases in Gaithersburg, MD, from Kite. The transaction was </font><font style="text-decoration:underline;font-weight:normal;">announced</font><font style="font-weight:normal;"> on July 19, 2021.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The acquisition strengthens BioNTech&#8217;s cell therapy pipeline by accelerating the individualized solid tumor Neoantigen TCR cell therapy research and development program. It also expands the Company&#8217;s cell therapy capabilities and manufacturing footprint in North America, building on its <font style="text-decoration:underline;">acquisition of Neon Therapeutics in 2020</font>. With three acquisitions completed in the last 14 months, BioNTech confirms its strategy of complementing organic growth through targeted acquisitions that expand its capabilities and accelerate development of its broad immunotherapy pipeline.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Kite employees at the Gaithersburg facility were offered employment with BioNTech prior to closing. The plant will be fully integrated into BioNTech&#8217;s US-operations and the global manufacturing network. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About BioNTech</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer. For more information, please visit&#160;<font style="text-decoration:none;">www.BioNTech.de</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About Kite</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with commercial manufacturing operations in North America and Europe. Kite&#8217;s singular focus is cell therapy to treat and potentially cure cancer. As the cell therapy leader, Kite has more approved CAR T indications to help more patients than any other company. For more information on Kite, please visit <font style="text-decoration:none;">www.kitepharma.com</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">About Gilead Sciences</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kite, the Kite logo and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information on Kite, please visit the company&#8217;s website at <font style="text-decoration:underline;">www.kitepharma.com</font> or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Follow Kite on social media on Twitter <font style="text-decoration:underline;">(@KitePharma</font>) and <font style="text-decoration:underline;">LinkedIn</font><font style="font-weight:bold;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Forward-Looking Statements</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains &#8220;forward-looking statements&#8221; of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding the expected impact of the acquisition on BioNTech&#8217;s business; the creation of long-term value for BioNTech shareholders; potential synergies between BioNTech and the acquired Kite assets; and BioNTech&#8217;s global expansion strategy. Any forward-looking statements in this press release are based on BioNTech management&#8217;s current expectations and beliefs of future </font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">events, and</font><font style="font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the reaction of third parties to the proposed merger, the retention of employees at the acquired sites, BioNTech&#8217;s plans with respect to the acquired assets, the future growth of BioNTech&#8217;s business and the possibility that integration following the proposed acquisition may be more difficult than expected, uncertainties related to the initiation, timing and conduct of studies and other development requirements for the acquired TCR product candidates; the risk that any one or more of the acquired product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future studies or trials;&#160; and risks related to BioNTech&#8217;s ability to protect and maintain the acquired intellectual property position.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a discussion of these and other risks and uncertainties, see BioNTech&#8217;s Annual Report on Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC&#8217;s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Gilead and Kite Forward-Looking Statements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. These and other risks, uncertainties and other factors are described in detail in Gilead&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, as filed with the&#160;U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Kite and Gilead, and Kite and Gilead assume no obligation and disclaim any intent to update any such forward-looking statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Contacts</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jasmina Alatovic, Media Relations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+49 (0)6131 9084 1513</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Media@biontech.de</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sylke Maas, Ph.D.,<font style="font-weight:bold;"> </font>Investor Relations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+49 (0)6131 9084 1074</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Investors@biontech.de</font> </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Kite Contacts</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mary Lynn Carver, Media</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1 (410) 443-1853</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jacquie Ross, Investors</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+1 (650) 358-1054</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gzrrpd4jxvgw000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzrrpd4jxvgw000002.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "* <L# 2(  A$! Q$!_\0
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M<#;UI,*.3BL/Q?X\\&^!/#,WC7QGXIL=+TFVC$DVI7MTL<*J>AWD@<G&/4G
MS7AWAW_@JW^P'XJ\46_A+2/VDM%^V7$ZPV_G1S11.[' &]T55^I( ZYQ5T<'
MBL3%RI0;2W:3=B:V.P>&DHU:B3>UV?1V0/X:<K%AFJ>FZA9ZMI\.J:;>1SV\
MT:R0S0R!D=2,AE(/((Y&,\5;5ACK7,XR3UZ'1&2DDT]!U%&1ZT%E'4TR@HH)
MQUHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"OO53EY:HZ[XK
M\+^&-.?5O$7B&RL;6/\ UEQ>72Q1K]6) %?*7[4_[ W[7WQ>L;-OA/\ \%'_
M !YHK6:RO);WEC:P_:9"!L7S=,2S9$ZYWK+U! !'/YT?M _\$T_^"KOP7N;[
MQ/=2ZYXUMYF^U:AJWA'Q!/?22R,V,-;R;+B5^A)6-ACJ3S4<\:=1<T9./5JS
M?R1]MDO".!SS#M4\RHTJKVC44DK]F[)?<?KUXT_;<_9E\$7'V/4?BII]Q)Y>
M]4TW=<JWMOB#*#[$UY3XP_X*O?"S3H@O@SP)K&IR;]K+>-':KM_O Y<G\A7X
MQQ?M.?'SX>:U<>'O'-CYEW:R>5=:;K6EFWGMW'52H",K?[P->@>$/VT/ >J,
MMOXLT2\T=F;#3)_I$*CU)4!_P"GZU]OD/^HN*FH8BK)2_O>ZOP_S/SWCOPS\
M>LEH2KY?AZ=:CNI47SNW>VY^@_C#_@JI\9]72XMO"7A/1]+CD_X]Y&5YIH_?
M)(0G_@->6^+/VROVE?&L_G:G\5-2A_=[&CTYA;(P_P!V, $^YYKR#0?%/AWQ
M39_VIX:UNUOH6_Y:6LP;!QT;'0^QP16B2"F[%?KF7Y!PW3IQJ8:E!KO\7XNY
M_'^?<1<<4<3+#YE5J4Y+>,DXM?*R+.I:[K>KDOJNKW-UN;<?M%PS9;U.>]5_
MW><8H)!&0].7IUKZ"G1I4](*R[)61\;4Q&(K2YJDFWW;;?WA1116AB%%%% !
M1110 4444 !IKG H\Q<]:VOA]\-_&GQ6\1P^%? .@W&HWDC#Y84^6-2?O,>B
MKZD\5E6KT<+2=2J^5+=O8VPV%K8RLJ5&+E)[):MF(?IS7T#^S+^P%\0_C-);
M^)O':S:#X>9P^9%VW%TG^P#]T'U//H.AKZ'_ &8/^">G@GX2I#XS^*K0ZUKJ
M?.L)YM;7_=! WL/[S?@!7CG_  4(_P""V/PS_9X6[^$W[,C6?BCQ=&LD%UJ2
ML&T_27''4<3R _P@[1CDGD5^;9AQ9CLVQ#P62P<K[SMMZ>7FS]LX?\.<'E="
M./S^:5M53ZOU/<_C%\>/V1?^"97PBWZ[=6MC,+?=INAVK*^H:I)T!QU()SF1
ML*,'J<"OQ^_;P_X*=_'O]M[7)]*U/4)=!\%QW6_3?"UG,=@ & T[@#SGQD\\
M#)P .*\/^*_Q=^)GQQ\:W7Q"^*_C'4-=UB\;,UY?SEVQV4=E4#@*,  ?2N;V
MMG.*][(>#</ETOK6,?M*SUN]4GY>?F>EG'$]3&4OJV#7LJ,=$HZ70)P..*<#
M\N#WH3/.*&R.I_*ON(Z'R6IZ-^R7^S[KO[4/[0OAGX+Z) S#5-00W\@'^IM5
M.Z5^&4_=[@YYK^D'X?>"="^''@W2_ WAFS6WL=*LX[>UA7^!44+CW_'.37YU
M?\&^O[(\OA7P)JW[5/BO2REYX@;['H'F*?EME/SR#C'S., CG (-?I<@(.-O
M6OY_X^SK^TLU]A3?NT]/5]6?N? N3_4,M]O->_4U]%T1P?[57_)L'Q%_[$/5
MO_2.6OYG>Y^M?TQ?M5?\FP?$7_L0]6_](Y:_F=SDGZU]-X7QC*CB+KK'\F?.
M^)4I+$4+=G^9]0_\$6A_QLQ^&9_VM6_],][7] #'::_ #_@BX?\ C9A\- ?[
MVK_^F>]K]VOBK\4?!'P:\":I\3/B/KT.FZ+H]JUQ?WMPV%1 .PZECT"CDDX%
M?.^(=.4^(U"$=XQT^;/:\/ZT:>1SG.6BDW?Y%/XX?&KX=_L]?#;5/BO\4O$4
M.F:+I5N9;B>9P"Q_AC0$Y9V/RJHY).!7X"?\% /V[/'O[<7Q@N/%NJM<67AR
MQ9H_#NAM+\L$63\[@<&1AR3VZ#ID[?\ P4=_X*+?$/\ ;N^);.LMQI?@?1[A
MQX:\/EL97I]JG X:=A]0BG:.2S-\TY!;KS7VW!?",<KHK%XM7J2Z/[*_S/D>
M+N*I9K5^KX:_LT]>[]!RJV !R?85^HG_  1U_P""3T>IOIW[5G[2?AO= NV?
MPGX=NDX8]5N9EY^J+Z\D=,<7_P $?_\ @E%JGQHU6P_:=_:#\//#X1M9!+X>
MT6\APVLN#Q,P).(%/J,N>AVC)_8VSL[>QM([&RA6&&&,)''&NU44#   [ 5X
MG&O%U/EE@,$U?:4E^2/8X-X6J2:QN,O;[,7U\V?DI_P<1?'?QF/'_A/]G*PN
M9+?0X=)_M:ZBAD*K=2L[QH'7@$($./\ >^E?F:2P.X'GK7[M?\%9_P#@FIJ/
M[<G@S3?%7POOK&S\;>'5<62Z@ D6HV[=8'D +*P(W(3E02P(&XL/S)\._P#!
M%_\ X*-Z]XJC\+W'P".FKYRK/J>H>(+'[+;HQ_UA>.9C(!U(C5FXZ=J]/@W/
MLAP^0QHU*BA*-^9-V=^^NYY?%V2YS6SJ52$').UK:JW8_0C_ (("_'[QE\5O
MV8-6^'/B^[FNAX+U2.WTZ\F8DFVF1G6+W"%&[GAL=A7W/XC\1Z-X3T&\\2^(
M+T6UC8V[SW5PR$^7&HR6P 3P/2O%O^">_P"QII/[#O[/-C\*$U2'4-8N)VO?
M$&I0QE4GNG !"9^;RU "KGKRV%+;1W_[2YW?L]^,?^Q<N_\ T4U?E.:U<)F&
M>3E07N3GI;UW^>Y^H9;#%9?D<57UG".OW7/&1_P6-_X)PK\A_:8LSW_Y >H9
M_P#2:NW^ O\ P4 _9'_:=\92> O@=\8;?7M6CMFN9+2/3;N';&.K9EB13^>:
M_G&V\=*^\?\ @WM '[9NH$_]"M/S_P "%?>9UP#@<MR>IC(592<5>SM;IY'P
M^4\<9AF&:T\+*$;2E;K<_;+D#FGI]VDS\^:7>OK7Y3$_5!:*3>@_BI-Z?WJH
M!U%('4G&:"Z#JU "T4@="<!J6@ HHHH **** "BBB@ HHHH **** "FR1AUP
M5IU!Z4 >7_'3]DG]G3]I'2?[)^-/PAT77@(6BANKNS7[3 K$;O*F&)(LX&2C
M*>*^ ?VJ/^#=[1+M+CQ-^R5\09K&7YG7PWXD8R0D]=L5PJ[U&. '#9/5P*_4
MH!NI%&/:LZE*G6^)7\SZK(>-.).&ZBE@L1**_E;O%^L7H?S0_%KX _M,?L=>
M-QIWQ(\&ZQX7U!3B"]&?)G4'DK*I*2KD<@$CU%=Q\*_VPDF:/1_BC:K'\NU=
M5MHS@X'\:C.,\\CC)Z <U^_?Q5^#?PV^-?A.Y\$_%#P7I^M:9=1E9;6^@$@Y
M!^89^ZPSPP(([$5^4W_!0K_@A7XB^'45Y\4_V1XKG5M+WM+>>%9?GGM4QG,+
M$YE'4;3\P&,9Y-=66YMG.05E4P51\O6+=U]VWW'Z'C<9X9^,>$_L[BS!PHXB
M2M&M!6U[WZ/UNCD]-U2PUBSCU+2KZ.Y@FC#1RPN&5P1U!^E65+]C7QQ\*OC)
MXQ^"^O2:;<QS-9^=Y=_I=QE3&RGYMH/W6'3WZ'H,?67@OQGH7CO0;?Q)X>O/
M.MYQGG@H>X([$5^]<)\:8+B2GR/W*J6L7U\T?PIXX?1_X@\)<;]8A^_P,W[E
M5=$]E*VB?GU-BBBBOM#^>0HHHH *#GM02!UI"PQUH 1MV/F--'L:V/!/@+QC
M\2-?A\,>"="GU"]F;"QPQ[MH]3Z#WK[D_9?_ ."<OA?X?BW\8_&1(=8U=?FC
ML-H:UM_]X'_6-^@KYW/>)LMR.G^\E>?2*W?^7S/KN%^"\YXGK?N8\M/K-WM_
MP6?/O[,_[!?Q(^.$T/B+Q,DVA^'BP8W,\9$URA_YY Y_[Z/'UK[*FC_9E_8+
M^$ESXEUN\T_P_I%A!NO-1NL&XNF'J1\\KGLH'T%>:_MS_P#!4GX!_L2Z')X:
MM)X=>\7-$R67AW3)%/V<@?*TQ_Y9J...I["OQ;_:G_;$^.W[8?CIO&GQB\4R
M7"QL1I^EVY*6EFF?NI'T^K'DU\'A\#Q!QM657$-T\.GHN_IW]3]NP^%X9X!H
M<F$BJN)MK)]/\O1'TK_P4/\ ^"T/Q1_:6>^^%OP'GNO"_@EI"DEY'(8[_5(^
MG[Q@?W<9_N#DCJ3TKX:S(SEW)9FY9B3D^^30JL&R:7D]J_4LKR? 9/AU1PT$
MN[ZM]VSXK,LTQF:8AUJ\[]ET7DD+1117J'G>\(2!Q7;_ +-_P0\2_M'?&_PY
M\&?"UO))<:WJ202-'&["&'.9)3M!(55!)." !7#O@G@U^K'_  ;W?LC+;Z;K
M'[67B[2?WERQTWPR9H^D8_UTPRO<X0,&[,#7SG%&;1R;*9UK^\U9>K/=X=RN
M6;YI"C]F]V_(_2+X/_##PU\&?AKHOPP\'6,=KINBZ?';6\<<:KD*H^8[0 23
MDDXY))KJ-WR\&FHI4;2*<1@\+7\SU)RJ5'*3NW=W[MG]&TJ<:--0BK)62]$<
M#^U5_P FO_$;_L0]6_\ 226OYFY!\Q/O7],G[57_ ":_\1O^Q#U;_P!)):_F
M:D^^W-?L/A;_  ,1ZQ/R7Q,_WG#^C_,^DO\ @D/XK\-^!/\ @H3X#\9>,-;M
MM.TK3;76KG4+Z]F$<<$*:-?,S.YX  !//0"NN_X*H_\ !3_7_P!MCQHWP]^&
M=U=Z?\-=%NC]BA?=%)K4RM@7<RGHG_/.(\J/G?#$*GQ\1CO3E+<D#\J^\J</
MX.MG2S*I[TDDDNBM?7UU/AZ>=8REE3P-/W8MW;ZOR] W!:_0#_@D=_P2;O/V
MAM2L_P!HK]H30YH?!%G.)-(T:8,C:W(O\3#J( >O]\C [FO"_P#@EK^SC\'_
M -IW]J[2_ /QG\4QV>FPQ-=PZ:S;6U62,Y%LIZ#/+'U"\<U_0-X?T31O"^C6
MGA_0;".TLK*!8;2V@3;''&HPJJ.@  KX[CSB>M@8?V?ADXR:NY>3[,^NX'X;
MI8Z?UVN[QCLO/S1-I>FV&C6,.EZ7:16]O;QK%;PPH$2- ,!54<!0!@ =.G%6
M]OR]*:"&'!HP:_$=9-M_>?LT4HI12LCXJ_X*V_\ !1GXQ_L%3^"X_A7X6T'4
MAXB%X;S^W(9G*>5Y6W9LD7^^<YS7QFW_  <5_M>]_A;X#_\  .[_ /DBO3/^
M#E$_Z;\*@!_#JF?_ "!7Y9OEA@5^U\&\-Y+F'#\,1B**E)WNW?H_(_&>+.(,
MVP.=SHT:S45;1'[B? #_ (*1_&+XJ_\ !-7QQ^V3KOA+P_#XC\,RZ@MG8VL,
MPLY/(BB==RM(6Y+G.&'X5\1^.?\ @O[^UAX_\':EX*U7X:^!X[;5;*2VGDAM
M+K<J.I4D9G//->U?\$_O!'BSXC_\$0OB=X(\">'KG5-8U+4-9@L-/LHBTMQ(
M;>W"JH[DFOA/6O\ @GA^W!X>TJXUW7/V7/&-K:VD+2W-S-I+*L:*,EB>P KD
MX?RWAM9ABJ>*4$XSM!2=K)=M3HSO,N('@:$J$IM2A>32NF_.R['BX'R_=(^@
M_P#K5Z[^QE^V/\1/V)OB=-\5?AKH6DZA?3Z>]HT&L1R-$$8]<(RG/'K7D@Z8
M&:ZCX4?!;XK_ !U\1-X0^#W@#4O$6I1P&>2QTFW,LBQ@\L1V%?I^.IX*M@I4
M\3;V;6M]%;U/SO!UL72Q49T+^TOI;<^V3_P<6?M?D8_X5?X#_P# .[_^2*_7
M'X!^/-4^*/P7\,?$/7+:WAO-:T.WO;J&U!$:O(@8A<DG'/')K^?O_AVQ^WJ/
M^;3?&O\ X)WK]W/@C?K\%/V1O#>H?$F*32O^$=\'P/JT=TNUK?RX1N5@>A!&
M/K7XMQG@<@HTZ*RSENVT^5W].K/U[@W'9U6J5I9@Y**5US*WKT1T/QR^//PH
M_9P\!77Q*^,?C2UT72+7 :XN6R78]$1%RSL>RJ"37YI?M$_\'&/B4ZM-I/[+
M7P;L4LX9L1ZUXP9Y#<*"0<6T+IM!ZAC*3CJ@/%?'/_!0/]N7XC?MN?&6Z\2Z
M[J$D/AS3;B2'PSHT;'RH(0<"1@>LC#DG&1T&!7F?P3^!7Q6_:)\>VOPW^#WA
M&YUC5KKE8;=?EC3^^[=$7U)KZ'(>!<MP>#^M9I9NU[-VC%>?F>'G?&F88S&/
M#9=I'9.UVV?0FN?\%N/^"C6L:O+J=E\:K/38Y)"18V/ANR\F+V7S8W?'U8FO
M8/@+_P '$?[07AG5+73OV@?AMH?B+2554N+[0XWL[T#O(07>*0_[*B,>XK#G
M_P"#>;]L*+P,?$J^-?"4FIK;^9_PCZW4OF[O^>8DV>7GWSBOB?XF?#/QQ\(/
M&M_\._B/X>FTO6--G,=W:7&,JWJ#T(]".#VKVL+EO!.>1E1PT8-KMHUYKJSQ
MJV/XOR>4:U>4HI]]O^ ?T=?LP?M4?![]K7X;6OQ/^#WB 75G+\MS:S?+<6DO
M>.5,G:P_7U->G*21G-?SN_\ !-7]KWQ3^R1^TIH^NVVL7">']8O([+Q!IZR'
MRYHV.T.5Y&5)R#P:_H6T?5;+6-.M]4L)@T-Q"LL3+T96&0?_ -5?D_%7#LN'
M\?R1;<):Q;W]#]3X7X@CGV"YI64XZ27ZEZBC.>E%?+GU 4444 %%%% !1110
M 4444 %%%% !1110 4R:-)8RKK3Z#R,4 ?FO_P %?/\ @DIIOQ1TO4?VE_V=
MM!CM_%%K$T_B#1;>,*FJ1@9:1!T$P'_??UYK\N_@)\7M3^%/BU;/4)7&E74N
MS4+=E/[LYQO [,/UK^F*YA6XB:&1 RL,,K=Q7X-_\%IOV5-+_9J_:TF\0>$K
M%+70?&T+ZG9VZ8"Q7(;%PJJ!PI9D;W+MVP*RAB*V5XN&.P[M*+N[=?ZZG[UP
M!F6#X^R/$<%9^O:4ZD&J;EJT[;*_;=>ECOK>YAO;>.[MI5>.15>-Q_$I&01[
M8YJ9<CC;7D_[)?CV;Q5X .@7UP6N=(?RP6(YB/W?<XZ?E7K R>JU_4>1YI2S
M;*Z6*A]I7:[/JOO/\N?$?@W&<!\98S),1_RZFTGWCT:]58<.E!YX--!4C@UJ
M>#?!'BOXA:[#X9\%Z#<:A>SL L-O&3MYZDC[H]S7I5JU/#TW.H[):W>B/C</
MAZV*J*E2BVWHDM6S*)(. ?PKV_\ 9I_8:^)/QWN8=;U>"31?#_F R7EQ&1).
MOI&O?Z]*^@?V8?\ @F]X=\'"W\8_&IX]5U)5W1Z2OS6T)[$_WV'Y5Z7^UA^V
MO^SY^Q%X#37?B;KL4-P\;#1] L5#7-VRKPJK_"O8L< >_2OS'.N-JV(J?4\H
MCS2;MS6OKY?YG[=PKX6TZ--8_/9<D%KR7W7F_P!$=%X!^%?P3_95^']Q>6$=
MGI%C96QDU/6KZ159E49+R2'^7 K\Z/\ @HC_ ,%TKS46OOA#^QO>&*+_ %5U
MXVV_,_\ >^SJ>W^V?P%?)G[=/_!3?X__ +;FMO9:UJ$F@^$X21:^&--F81L,
M\-*W_+5NG7@=A7SB%8<"NOA_@>7M?KF;2YYO7E;O][ZGTF<<74J=#ZEE4%"E
M'2Z5ON7ZEC6M:UCQ-K-QXA\0ZG/>WMY,TMU>73F1Y7)R68GOGN:A%-(/0K0%
MPV:_3*=.-.*C%62V2/S^4I3DYS>XZBBBK *#137X7.* .H^!_P )/$OQX^+?
MA_X2>#[1IK[7=2CMXU09V*6^9SZ*JY8^PK^DKX"?"3P[\"OA'X?^$OA6V6*Q
MT/38K6/:@&\JHRQQU+'))[DYK\RO^#>S]D5M2UG6/VN/%NG,(;/?I?A@30D;
MI#CSIU)'.!A P/4N#7ZR185L$U^"^(6=?7LR6$IOW*>_^+K]Q^U\!9/]3P/U
MJHO>GMZ=/O)<=\4U^E.IK]*_/3]!//\ ]JK_ )-@^(O_ &(>K?\ I'+7\S<A
MY;ZU_3)^U5_R;!\1?^Q#U;_TCEK^9QAEVSZU^Q>%O\#$>L?U/R'Q,_WC#^C_
M #/3/V./V=)?VLOVC-#_ &?H=>_LN;7[74?LM\T6\1SP:?<W$>Y?[I>)0V.=
MI.*Y;XO?"/Q_\!_B/JWPH^)VA2:?K6BW;07D#?,#@X#HW\:,,%6'!!KW_P#X
M(O G_@I?\,S_ +6L?^F>^K],_P#@J]_P3.\/?ME_#^7XC> +*.S^(F@6;?V;
M<+\JZG"H+?9)?7G.QNJL?0D5[>9\52R?B=87$/\ <RC'Y/77T/#R[AN6;</R
MQ-#XXR?S1^&.A:_KGA;6[7Q'X<U*>QOK*=9K.[MI2KPR*00P(Z$8S7[>_P#!
M)7_@IY:?M?\ A%?A-\5[R&#X@:+:C?)N"C5H5&/.4=I!QO XYR*_$'5M)U/P
M_J]UH&MV$UK>V5P]O>6TT95X9$;:RL.Q!!&*U?AK\3/&GP?\<:=\1_AUK]QI
MFK:7<+/9W5LYRI!_(@]QWKU>).'\+Q'@M+*=KQDOU\F>?P]GF)X?QVJ?*W:4
M?U/ZA%,:KS02&VE:^6?^"9__  4=\'?MR_#=;/5C#IOC;1X577-)WC;-Q_Q\
M0^J$]1U4^V#7U.H.WI7\[XW!XC+\5*A7C:4=_P#@>1^_X+&X?'X>-:B[I_U8
M_*S_ (.4?^/SX4C_ &-4_P#:%?EF1D=*_4K_ (.4N+WX4_[NJ?\ M"ORUK]\
MX!_Y)FGZR_,_"N-_^2CJ_+\D?MU_P;X#/["MS_V/%_\ ^BK>OJS]IK_DW_QG
MQ_S+MW_Z*:OE/_@WO_Y,5N?^QXO_ /T5;U]6_M.'_C'[QE_V+MW_ .BFK\;S
M;_DJ*G_7S]3]:RG_ ))>/^#]#^9?M7W?_P &^*_\9FZA_P!BO/\ S%?!ZD8Z
MU]W_ /!O@1_PV?J7/_,KS_\ H0K]PXJ_Y)>O_A_R/QGAG_DHJ/\ B/VR.,U\
M<?\ !<7XHWWP[_89UC2M'U22UN?$%]#8#9C]Y$3F1#GL1Z5]CLR \&OA3_@X
M \&77B+]C"#Q' X"Z+K\,DJ^N_Y*_!>'8TZF=T(U-N9?\#\3]RXBE4ADM>4-
M^5GXDJ.,'\>:^COV!/\ @HIK'[ [:YJ'A;X+Z+X@U+7&C1M2U&\EBDAB7_ED
MNU2-I//K7SB-_3%>F?L^_L<_M#_M30ZA/\"/AZVO?V5(J7R0WL$;Q;AP=LCJ
M<'U QGOVK^CLTHY;B,$X8QKV3M>[LO+4_GS+:V.I8M3POQK:RNS[8'_!R/\
M&L+C_AG#PU_X.+C_ .)KY#_;C_;/UK]N#XHVGQ3\0_#C2_#MY;V"VLD.ES,X
MGP<AV9@"2.G>NO;_ ((^_P#!1,\_\,XW_P#X,K7_ ..TUO\ @D#_ ,%$1\K?
MLZ7W_@SM?_CM?-Y;A^"\KQ"KX:I!2UUY_P#@GOYA6XLS##^SQ,)./1<O_ /F
MHDK\RU_1;_P3>^(<_P 4_P!BWP#XLGA\MFT2.$K_ -<_ES^E?C0/^"/W_!1,
MC_DW*^_\&5K_ /':_93_ ()J_"GX@_!']C?P;\-/B?X=DTO6M-LV2]L9I%=H
MFW'C*DCI[U\SXB8_+<=@:3P]2,I*71INUO(^DX P.88/'U56IN,6NJ:5_F>]
M!OEYIU- 8TZOR,_6@HHHH **** "BBB@ HHHH **** "BBB@ H.,<T4CXV\T
M 1';Z5^<?_!Q9\,Y]<_9W\+?$BPTF.1M"\2*E]>X&^*"6-D"Y]#(8\C\:_1S
M\.]?%O\ P7E7/_!/K7@>VM:;_P"E<=98B/-AY+R9]EX>XJI@^,\%4AO[2*^3
MT?YGY"_L<Z[/I_Q-DTE OEW]FZR;NVWYACWR*^I-^#\U?)/[)OAWQAXO^/WA
M[PUX(T"ZU&]O+Q8EM;6!I&96XSP#@>YK]H/V7O\ @FII'AT6_C/X]>5?Z@OS
M0Z!&P:W@.>#(P/[T_P"R/E^M?I7 G%6#R?AN4<0_>B_=BMWI?Y+S/@_I<>'>
M-SSQ9HU\#%6JTDYR>B5G;7SMTW/GO]FK]BOXF_M!WT.J26LFD^'1)^^U2XC(
M,@[^4I^^??[H]^E?H%\%?V?/A?\ L^>&O[-\':5%$RQYO-2GP9I\=6=R/TX
M]*L?%[XT_!O]F?X>S>-_BKXNT[P[HMC'MC:9ECW$#Y8HTZNQZ!5!-?CK_P %
M#?\ @L_\5OVH6OOAE\$/MGA/P*ZM!=,' O-67/61AS$A'_+-3R/O$] I5^(.
M.,5RQ]RBGK_*OGU?]:'YGE>0<-\ X92M[7$/K;WO1+HCZ_\ ^"B/_!;3X>?
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MI-W;;;]6?TC0HPH453@K)))?(=37Z4ZFN>,5)J>??M6?\FO?$;C_ )D/5O\
MTCEK^9XCYF/O7]-'[36G:EK7[.7C[1M&L)KJ\NO!>J0VMK;QEY)I&M9%5%50
M2S$D   DD\5_/"?V,?VP,L!^RQ\1,;NO_"&WOY_ZKI7ZUX9XK#8:EB%5FHW<
M=W8_*?$;"XC$8B@Z<6[)[*YZO_P1;S_P\P^&G^]JW_IGO:_?V19#E17X=?\
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M&5@>H(R#7Y\?\$U/^"*FC?LX:Y9_&W]I&\L==\76ZA]+T6VC$EII,G]\L?\
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MEN29%&!@[QGI7AO_  1?^.OQ=^/G[*UWXQ^,OC^^\0:I'K4T*WM\5W! !A>
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MOC;X,^(/P@TGXSG58-.TG4M/2Z:;4)5A6 ,.0Y;A<&M#P?\ %_X4^/;R33_
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M>MPTJL,JRC?DA@00>^>*_.3X,F#P1X _;8^!_A6UCL/#'AW4M1_L31X5(AM
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MP7_;OU'P2/%^M37]S::/H\\;;7=F5'>.[3?MW$9P/H,U[3^Q9^Q/^U7^SO\
M$;4/%OQN_;<U[XC:9>:2UI!H^IPSJD$QD5A-^\N9!D!2OW1]X\]C]3_\M5IW
M\/XUG"G&/WM[O_,]3%<69QCL(J%9Q:LE?DCS66RYK7_$_/;QU_P1T_:(F_:,
M\7?M ?!?]MJY\%7'BN[:2:+2]#E$J1$J?+:1+I=XRH/3&>U>J?LC?L0?M@_
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gzrrpd4jxvgw000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzrrpd4jxvgw000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ B(# 2(  A$! Q$!_\0
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MO?K7I5UX-\/W;EWTV-&(Q^Y)C _!2!^E<AKGPXEMH&N-)F>X"C)@DQO/K@C
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ML\F,;Y858X],D5]&<V(I.K#E1X%17N_]@:-_T"+#_P !D_PH_L#1O^@18?\
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MW%K*T4R;-KJ>1EU!_0UY7_PE>O?]!6Y_[ZH.6MBHTI<K1[A17A__  E>O?\
M05N?^^J/^$KU[_H*W/\ WU2N9?VA#LSW"BO#_P#A*]>_Z"MS_P!]4?\ "5Z]
M_P!!6Y_[ZHN']H0[,]PHKP__ (2O7O\ H*W/_?5'_"5Z]_T%;G_OJBX?VA#L
MSW"BO#_^$KU[_H*W/_?5=5X!UO4]2UV>&]O99XUMF8*YR =RC/ZFBY=/&PG)
M12W/1J\3\7WK7WBJ_<[@L<GDJK'. GR\>@)!/XU[97@6J2F?5[V8@@R3NQ!]
MV)H9GF#]Q([KX:Z/&4GU>5 7#&&'(^[Q\S#ZY S]?6O0ZYWP+_R)MA_VT_\
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M2]FVE:QPO@C7KC3-:@LB[-9W<@C>/&<.>%8>ASC/MZX%>P5X1H'_ ",FE_\
M7W%_Z&*]WH1& DW!I]#R/XB?\C4W_7!/ZUL?"W_F+?\ ;'_V>L?XB?\ (U-_
MUP3^M;'PM_YBW_;'_P!GHZF%/_?/FSN=5MWO-'O;:+'F36\D:Y/<J0*\"KZ(
MKPOQ%I;:/KMU:;-L8<M#UP4/*\GKQP?<&AFF80=HR/8] O!?^'["Y\SS&>!=
M[>K@8;]0:T:\M\#>*XM+)TS4'*VLC9BE)XB8]0?13Z]C]21ZA'(DL:R1NKQN
M RLIR&!Z$&F=>'JJI!-;CJ***#<***K7VH6FF6IN;VX2&(<;F/4^@'4G@\"@
M3:2NSDOB9<HFAVMMOQ)+<;@N.JJIS^K+7#>$[8W?BK38P<;9A)_WQ\W_ ++1
MXFUY_$&KM<@,EN@V0QL>57U/N>OZ<XK?^&NEM-JD^I/'^ZMTV(Q!^^WIVX7.
M?]X4CR)2]OB5;;_(]0KB=?\ ^0W<?\!_]!%=M7$Z_P#\ANX_X#_Z"*\?//\
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M=?\ ^0W<?\!_]!%=M7$Z_P#\ANX_X#_Z"*\;//\ =X^OZ,ZX[FSX6_X\9O\
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M^_;_ /Q=<910'UFM_,=G_P +,UG_ )]K#_OV_P#\71_PLS6?^?:P_P"_;_\
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&112/*/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
